EP0552297A1 - Hepatitis c virus antibody - Google Patents
Hepatitis c virus antibodyInfo
- Publication number
- EP0552297A1 EP0552297A1 EP91920333A EP91920333A EP0552297A1 EP 0552297 A1 EP0552297 A1 EP 0552297A1 EP 91920333 A EP91920333 A EP 91920333A EP 91920333 A EP91920333 A EP 91920333A EP 0552297 A1 EP0552297 A1 EP 0552297A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibody
- virus
- plasma
- hepatitis
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000711549 Hepacivirus C Species 0.000 title claims abstract description 13
- 239000000427 antigen Substances 0.000 claims abstract description 34
- 102000036639 antigens Human genes 0.000 claims abstract description 34
- 108091007433 antigens Proteins 0.000 claims abstract description 34
- 241000700605 Viruses Species 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000002245 particle Substances 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 16
- 238000003556 assay Methods 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 11
- 229920000515 polycarbonate Polymers 0.000 claims description 10
- 239000004417 polycarbonate Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000011148 porous material Substances 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 210000004408 hybridoma Anatomy 0.000 claims description 5
- 241000282579 Pan Species 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 238000010324 immunological assay Methods 0.000 claims description 2
- 208000037319 Hepatitis infectious Diseases 0.000 claims 2
- 208000005252 hepatitis A Diseases 0.000 claims 2
- 230000008105 immune reaction Effects 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 abstract description 3
- 210000002381 plasma Anatomy 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 8
- 241000282577 Pan troglodytes Species 0.000 description 7
- 239000012678 infectious agent Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 238000001493 electron microscopy Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000617996 Human rotavirus Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 240000008791 Antiaris toxicaria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 238000012808 pre-inoculation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to antibodies which selectively bind to antigens associated with hepatitis C viral particles isolated from infected patients and to processes for isolating hepatitis C virus from plasma including a procedure by which HCV is partially purified.
- hepatitis C virus or HCV HCV has historically been referred to as non-A non-B hepatitis or NANBH
- HCV hepatitis C virus
- NANBH non-A non-B hepatitis
- the prevention of the transmission of this form of hepatitis by blood and blood products requires reliable, sensitive and specific diagnostic and prognostic assays which may be used to identify HCV carriers as well as contaminated blood and blood products.
- the present invention relates to an antibody capable of selectively binding with one or more HCV antigen which are associated with the whole virus particle and which produce an immune response in a patient.
- HCV antigens associated with the virus particle are isolated from a mammal selected from the group consisting of chimpanzees and humans.
- Both monoclonal and polyclonal antibodies are provided by this invention. Both of these types of antibodies may be prepared according to processes known in the art for generating hybrido a cells from immuno-challenged mammals. Specifically, these antibodies may be isolated from cell lines selected from the group consisting of the hybridoma cell lines H18 C27 and H18 C68 which were deposited on August 15, 1990 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, 20852 under ATCC Nos. HB 10529 and HB 10530, respectively.
- ATCC American Type Culture Collection
- This invention also provides a process for isolating an infectious HCV particle in a plasma sample taken from an infected patient which includes clarifying the plasma sample by centrifugation; filtering the clarified plasma through a series of filters having sequentially smaller pore sizes, wherein the pore size of the filters is 3.0, 1.0, 0.8, 0.6, 0.4, and 0.2 microns, respectively; pelleting the filtered plasma through a 10% sucrose solution; and resuspending the pelleted material.
- the present process provides resuspended material having infectivity titers up to and about 10 7 CID/ml even though this material contains less than about 1%, and preferably less than 0.1%, of the total pelletable protein of the original plasma sample.
- the antibodies of the present invention are useful in an immunological assay for detecting an antigen specifically associated with HCV.
- the present invention provides a method to isolate and visualize the agent(s) known to cause human and chimpanzee HCV.
- Past efforts to immune aggregate a putative virus, raise hyperimmune sera, or clone this illusive agent have been thwarted by the lack of availability of adequately purified virus from blood plasma. Little was known about the physical properties of this infectious agent except that it is probably a chloroform and B-propiolactone sensitive virus capable of passing through about a 100 n filter. Attempts by others to determine the bouyant density of the virus have yielded ambiguous results and, until now, there has not been a reliable means for purifying and, at the same time, concentrating the virus.
- the present invention describes a scheme for purifying and enriching whole, infectious blood plasma and using the isolate to generate antibodies.
- polycarbonate filters are preferred because, unlike nitrocellulose, polyester or other types of filters ; -rf ⁇ ich are made of a relatively thick meshwork of interwoven fibers, polycarbonate filters are thin and contain precisely sized, straight-bore holes. These features limit the loss of particles caused by non-specific absorption or entrapment in the filter matrix associated with nitrocellulose, polyester or other types of filters.
- Table 1 illustrates a preferred scheme to isolate HCV particles.
- Whole blood plasma was first clarified by low speed centrifugation and then sequentially pressure filtered through 3.0, 1.0, 0.8, 0.6, 0.4 and 0.2 micron Nuclepore filters. The 0.2 micron filtrate was then layered on top of buffered 10% sucrose and pelleted for 4 hours at 105,000 x g. Following pelleting thru 10% sucrose, fine protein was removed. Pellets were resuspended in phosphate buffered saline to yield a 10OX stock concentrate and then further diluted as desired. The portion of the final concentrate to be used for infectivity studies was diluted in buffer containing 2% BSA as a cryroprotectant. TABLE 1
- Step #4 0.8 Micron Filter
- Step #9 Resuspend to 100 x
- the partially purified plasma passed easily through the filters and at each step of the purification process 100 microliter aliquots of .plasma were prepared for electron microscopic viewing using a method developed by Miller (Miller, M.F., Electron Microscopy in Biology, Vol.2, J.D. Griffith, ed., John Wiley and Sons, Inc., New York, N.Y., 1982, pp. 305-339) which employs the commercially available Beckman Airfuge ultracentrifuge and Em-90 electron microscopy particle counting rotor.
- the filtration procedure may be used to provide concentrated plasma needed to isolate the infectious agent associated with HCV.
- One method to isolate HCV immune aggregation electron microscopy, may be performed by mixing appropriate concentrations of the plasma concentrate and a suitable antibody and visualizing resultant immune aggregates using a transmission electron microscope.
- the antibody is generally pre-centrifuged at about 40,000 RPM for 10 minutes to remove undesirable background particulates found in most sera.
- the preferred aggregation procedure to study a variety of hepatitis viruses includes: a) mixing 20 microliters of well dispersed plasma concentrate with 50 microliters of PBS, pH 7.2, and 20 microliters of antibody, b) incubating the mixture for one hour at room temperature and then overnight at 4°C, c) pelleting the immune aggregates for 30 minutes at 20 psi in a Beckman Airfuge Ultracentrifuge, d) discarding the supernatant and resupsending the pellet in 20 microliters of water, e) applying 5 microliter droplets of suspension to Formvar coated EM specimen grids, f) blotting away the droplet with absorbent paper, and g) negatively staining adherent particulates with 2% phosphotungstic acid. Specimen grids are then carefully surveyed for immune aggregates with a transmission electron microscope at magnifications ranging from 10 to 45,000 x.
- the monoclonal antibody or other monoclonal antibodies derived using the described isolated HCV preparations may be used in diagnostic tests for antigens of HCV separately, in combination with each other or in combination with human, chimpanzee, rabbit or other mammalian polyclonal antibodies.
- the antibody may be bound to a suitable solid support, contacted with a sample or aliquot containing HCV, and then contacted with a second labeled antibody which may be developed to provide a detectable signal.
- a second labeled antibody which may be developed to provide a detectable signal.
- An assay which uses antibody of the present invention which has been labeled with a signal generating moiety is an alternative procedure.
- the labeled antibody may be used in a competitive antibody assay. In this type of assay, the labeled antibody is incubated with the sample or aliquot in the presence of a solid support which is coated with an antigen containing the immunodominant epitope of the antigen contained in the sample.
- Antibodies to HCV present in the sample will compete for binding with the labeled antibody and with the bound antibody. Therefore, a sample containing an antibody to HCV will produce a detectably lower signal compared to the signal produced in an assay which has no added labeled antibody.
- the purified virus prepared by the process of this invention may also be used to characterize unknown HCV antigens.
- the purified virus used to generate an antibody may be labeled with radioactive iodine using both Chloramine T and Bolton Hunter reaction conditions according to established procedures before and after solubilization of the virus with detergents.
- the antibodies may be used in an immunoprecipitation experiment where the antibody is allowed to react in solution with the solubilized labeled virus. After this incubation period, several micrograms of fixed Staphalococcus aureus (Staph A) cells are incubated with the antigen-antibody mixture. Immunoglobulin receptors on these cells will bind the antigen-antibody complexes as well as free immunoglubulins.
- the bound cells are pelleted by centrifugation and washed repeatedly to remove unadsorbed labeled antigen.
- the Staph A cells with the adsorbed complexes are then dissociated by heating to 100°C in a solution containing 2- mercaptoethanol, detergents and buffer and then electrophoresed on polyacrylamide slab gels. After electrophoresis the gels are fixed, treated with chemicals known to enhance detection of radioactivity, dried and exposed to x-ray film at -70°C for an extended period of days, weeks or even months.
- the x-ray film bands will appear on the film at positions where the radiolabeied antigens migrated in the gel based on their molecular size. By comparing the positions of these bands to those of radioactive standards of known molecular weight, the molecular size of the precipitated viral antigen can be determined. The information may be valuable in the determination of the size of the actual gene products of HCV which are unknown at this time.
- Variations of this technique may also be utilized to identify labeled viral antigens produced in cell lines capable of supporting viral replication. In essence, this technique can be used to screen various cell lines for the presence of viral replication and therefore is useful as a tool for establishing a tissue culture system for hepatitis C diagnosis.
- monoclonal antibodies according to the invention will be useful in assays for detecting HCV infection and infectious agents in bodily fluids, tissues, experimental reagents and fluids.
- the monoclonal antibodies of the invention may also be used to isolate antigens specifically associated with HCV by affinity chromatography. Such immunopurified antigen may be used to immunize non-primate species such as goats and rabbits, in order to obtain antibodies having* multiple epitope specificities. Alternatively, the isolated antigen may be used to immunize mice or rats allowing for preparation of hybridoma cell lines capable of producing additional monoclonal antibodies.
- Antibodies generated according to the present inventions will allow the characterization of antigens specifically associated with HCV infection and infectious agents.
- standard methods such as analytical and preparative gel electrophoresis may be employed to determine the molecular weight of antigens reactive with the antibodies of this invention.
- Reactive isolates so obtained may be subjected to further characterization through use of various selective agents including reducing agents, proteases, upases, glycosidases, and the like.
- Antibodies which react with ' HCV viral antigens may be utilized in a variety of immunoassays including competitive and non-competitive immunoassays, radioimmunoassays, ELISA, EIA and the like.
- Example 1 describes a process to purify HCV from an infected chimpanzee
- Example 2 describes the production of a monoclonal antibody
- Example 3 describes a diagnostic test.
- Chimpanzee blood plasma having an infectivity titer of 10 5 CID/ml (chimp infectious doses/ illiliter) of HCV was purified as follows.
- Raw plasma was first clarified by low speed centrifugation for 20 minutes at lOOOXg in a tabletop centrifuge to remove large cellular debris and then sequentially pressure filtered through polycarbonate membrane filters having pore sizes of 3.0, 1.0, 0.8, 0.6, 0.4 and 0.2 micron diameter. Particulates remaining in the 0.2 um filtrate were then pelleted by ultracentrifugation through phosphate buffered 10% sucrose for 4 hours at 105,000 X g. This step removed fine proteins and served to concentrate the virus.
- Pelleted virus was resuspended in phosphate buffered saline to yield a final 100X concentrate.
- the portion of the concentrate to be used for infectivity studies was diluted with buffer containing 0.2% Bovine Serum Albumin as a cryoprotectant.
- Electron micrographs showing sedimented and thin-sectioned particulates derived from the purified chimpanzee plasma were compared to the similarly prepared raw starting plasma. Using a sensitive spectrophotometric assay it was found that total pelletable protein was decreased more than 250 fold. When purified virus product was inoculated into chimpanzees it was found to be infectious (100% of titer recovered as evidenced by the characteristic elevation of serum enzymes and appearance of hepatocyte ultrastructural alterations). The purified product was used to generate monoclonal antibodies.
- mice Six female Balb c/J mice were selected on the basis of low reactivity of their sera by immunofluorescent microscopy on liver sections from hepatitis C infected chimpanzees. These selected mice were used for inoculation with purified HCV. Pre-inoculation bleeds were collected from all mice prior to inoculation with virus. Purified virus obtained by the procedure described in Example 1 was used as the inoculum.
- IP intraperitoneally
- mice Two mice each were inoculated according to the following regimen: intraperitoneally (IP) with 0.1 ml of the purified virus stock, 0.2 ml of a 1/10 dilution of the virus stock in normal saline, or 0.2 ml of a 1/100 dilution of the virus stock in normal saline.
- Blood samples were collected by eye bleeds at day 21.
- all mice were boosted (IP) with the same inocula and dose as their primary immunization regimen.
- Blood samples were again collected by eye bleeds on day 49.
- IV intravenously
- the IV boosted mice were sacrificed and their spleen lymphocyte cells were isolated and fused to SP 2/0 mouse myeloma cells following the procedure of Kohler and Milstein (Kohler G., and Milstein C, Nature, 256:495-497, 1975).
- the remaining 3 mice were boosted IV as previously described, and sacrificed three days later and their spleen lymphocytes were isolated and fused to SP 2/0 cells.
- the monoclonal antibody prepared according to the procedure of example 2 is used as an antigen capture reagent bound to a solid phase polystyrene bead support.
- An aliquot of bodily fluid such as serum, plasma or cerebral spinal fluid from a patient is incubated with the antibody bound to the bead.
- an antigen or whole virus binds to the solid phase.
- unbound antigens are washed away from the solid support.
- the same antibody, or another monoclonal antibody binding to a different epitope of an HCV antigen, or a polyclonal antibody, coupled to horseradish peroxidase is incubated with the bead.
- This labeled antibody will bind to antigen trapped on the solid phase forming an antibody-antigen-antibody sandwich. Excess peroxidase labeled antibody is washed away and the bead is exposed to a suitable enzyme substrate such as OPD (orthophenylene diamine) . The resulting colored product is detected spectrophotometrically in amounts directly proportional to the amount of antigen which was present in the original aliquot.
- OPD orthophenylene diamine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59681190A | 1990-10-12 | 1990-10-12 | |
US596811 | 2000-06-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0552297A1 true EP0552297A1 (en) | 1993-07-28 |
EP0552297A4 EP0552297A4 (ja) | 1994-02-09 |
Family
ID=24388816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91920333A Withdrawn EP0552297A1 (en) | 1990-10-12 | 1991-10-09 | Hepatitis c virus antibody |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0552297A1 (ja) |
JP (1) | JPH06502075A (ja) |
KR (1) | KR930702506A (ja) |
AU (1) | AU663064B2 (ja) |
CA (1) | CA2093919A1 (ja) |
TW (1) | TW216797B (ja) |
WO (1) | WO1992007001A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0556320T3 (da) * | 1990-11-07 | 1999-10-18 | Abbott Lab | Monoklonale antistoffer mod Hepatitis C-virus og fremgangsmåde til anvendelse heraf |
JP3217600B2 (ja) * | 1994-07-12 | 2001-10-09 | 株式会社先端生命科学研究所 | 非a非b型肝炎ウイルス関連抗原のイムノアッセイ、それに使用するモノクローナル抗体、およびこの抗体を産生するハイブリドーマ |
CN103965301A (zh) | 2003-04-01 | 2014-08-06 | 国家健康医学研究所 | 针对丙型肝炎病毒e1e2复合体的抗体、hcv颗粒的组合物和药物组合物 |
US8551484B2 (en) | 2007-02-21 | 2013-10-08 | University Of Massachusetts | Human antibodies against hepatitis C virus (HCV) and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3886363T3 (de) * | 1987-11-18 | 2004-09-09 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | NANBV-Diagnostika |
AU632271B2 (en) * | 1988-03-30 | 1992-12-24 | Abbott Laboratories | Production of monoclonal antibodies specific for non-a, non-b hepatitis infected liver |
-
1991
- 1991-10-09 EP EP91920333A patent/EP0552297A1/en not_active Withdrawn
- 1991-10-09 CA CA002093919A patent/CA2093919A1/en not_active Abandoned
- 1991-10-09 JP JP3518583A patent/JPH06502075A/ja active Pending
- 1991-10-09 KR KR1019930701073A patent/KR930702506A/ko not_active Application Discontinuation
- 1991-10-09 WO PCT/US1991/007571 patent/WO1992007001A1/en not_active Application Discontinuation
- 1991-10-09 AU AU89457/91A patent/AU663064B2/en not_active Expired - Fee Related
- 1991-11-02 TW TW080108674A patent/TW216797B/zh active
Non-Patent Citations (2)
Title |
---|
No further relevant documents disclosed * |
See also references of WO9207001A1 * |
Also Published As
Publication number | Publication date |
---|---|
KR930702506A (ko) | 1993-09-09 |
EP0552297A4 (ja) | 1994-02-09 |
CA2093919A1 (en) | 1992-04-13 |
TW216797B (ja) | 1993-12-01 |
AU8945791A (en) | 1992-05-20 |
WO1992007001A1 (en) | 1992-04-30 |
JPH06502075A (ja) | 1994-03-10 |
AU663064B2 (en) | 1995-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Anderson et al. | Diagnosis of human parvovirus infection by dot‐blot hybridization using cloned viral DNA | |
DE69131488T2 (de) | Kombinationen der Hepatitis-C-Virus (HCV) Antigene zur Verwendung in Immuntests für Anti-HCV-Antikörper | |
JP3490085B2 (ja) | 構造エピトープを有する抗原を用いる抗hcv抗体のイムノアッセイ | |
Mehta et al. | Quantitation of measles virus-specific immunoglobulins in serum, CSF, and brain extract from patients with subacute sclerosing panencephalitis | |
US5110738A (en) | Monoclonal antibody capable of recognizing arteriosclerotic lesions and agents for detecting and treating arteriosclerosis | |
US3994870A (en) | Purification of hepatitis B surface antigen | |
KR102000479B1 (ko) | 항인간 노로바이러스 gii 항체 | |
Gerin et al. | Biophysical Characterization of the adr Subtype of Hepatitis B Antigen and Preparation of Anti-γ Sera in Rabbits | |
Dreesman et al. | Production of potent anti-Australia antigen sera of high specificity and sensitivity in goats | |
JPS58183629A (ja) | 非a非b型肝炎関連モノクロナ−ル抗体および診断薬 | |
KR930001278B1 (ko) | B형 간염 표면 항원(HBsAg)에 대한 모노클로널 항체의 제조방법 | |
Hirashima et al. | Regulatory role of IgE-binding factors from rat T lymphocytes. IV. Formation of IgE-binding factors in rats treated with complete Freund's adjuvant. | |
CA2252466C (en) | Hepatitis b monoclonal antibodies | |
JPH0250426B2 (ja) | ||
JPH08242849A (ja) | 限外濾過によるタンパク質溶液からのウイルスの除去 | |
AU663064B2 (en) | Hepatitis C virus antibody | |
KR930000186B1 (ko) | 비-a, 비-b형 간염 감염된 간에 대한 모노클로날 항체 | |
Ma et al. | Multiple sclerosis serum and cerebrospinal fluid immunoglobulin binding to Fc receptors of oligodendrocytes | |
EP0068465B1 (en) | Non-a, non-b hepatitis-associated antibody conjugate, the use thereof and detection reagent | |
SANTOS et al. | Trypanosoma cruzi: binding of parasite antigens to mammalian cell membranes | |
Kojima | Immune electron microscopic study of hepatitis B virus associated antigens in hepatocytes | |
JPS63123395A (ja) | 抗pciモノクローナル抗体、これを用いた抗pciの精製法及び免疫学的測定法 | |
EP0308242B1 (en) | Agglutination assay | |
US5419906A (en) | Preparation of human immunoglobulin free of hepatitis C | |
US5162224A (en) | Monoclonal antibodies specific for b cells and htlv-i transformed t cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19930302 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
RHK1 | Main classification (correction) |
Ipc: C12P 21/08 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19931220 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19950731 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19951212 |